

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6292823

| | |
|---|------------------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | ASSIGNMENT |
| CONVEYING PARTY DATA | |
| Name | Execution Date |
| MOSAIC BIOMEDICALS, S.L.U. | 08/21/2020 |
| RECEIVING PARTY DATA | |
| Name: | MEDIMMUNE LIMITED |
| Street Address: | MILSTEIN BUILDING |
| Internal Address: | GRANTA PARK |
| City: | CAMBRIDGE |
| State/Country: | UNITED KINGDOM |
| Postal Code: | CB21 6GH |
| PROPERTY NUMBERS Total: 6 | |
| Property Type | Number |
| Application Number: | 62467017 |
| Patent Number: | 10583191 |
| Patent Number: | 10206999 |
| Application Number: | 16470896 |
| Application Number: | 62774460 |
| Application Number: | 62943479 |
| CORRESPONDENCE DATA | |
| Fax Number: | (301)398-9306 |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | |
| Phone: | 3013980000 |
| Email: | patents@astrazeneca.com |
| Correspondent Name: | MEDIMMUNE LLC |
| Address Line 1: | ONE MEDIMMUNE WAY |
| Address Line 4: | GAITHERSBURG, MARYLAND 20878 |
| ATTORNEY DOCKET NUMBER: | LIF IP ASSIGNMENTS |
| NAME OF SUBMITTER: | KORTNI L HAYES |
| SIGNATURE: | /Kortni L Hayes/ |
| DATE SIGNED: | 09/10/2020 |

Total Attachments: 8

source=LIF IP Assignment (26 August 2020)#page1.tif

source=LIF IP Assignment (26 August 2020)#page2.tif

source=LIF IP Assignment (26 August 2020)#page3.tif

source=LIF IP Assignment (26 August 2020)#page4.tif

source=LIF IP Assignment (26 August 2020)#page5.tif

source=LIF IP Assignment (26 August 2020)#page6.tif

source=LIF IP Assignment (26 August 2020)#page7.tif

source=LIF IP Assignment (26 August 2020)#page8.tif

INTELLECTUAL PROPERTY ASSIGNMENT

THIS INTELLECTUAL PROPERTY ASSIGNMENT (this “**Assignment**”), effective as of August 26, 2020 (the “**Effective Date**”), by and between **MOSAIC BIOMEDICALS, S.L.U.**, a Spanish limited liability company (“**Seller**”), and **MEDIMMUNE LIMITED**, a private limited company incorporated in England and Wales (“**Assignee**”).

Seller and Assignee are sometimes referred to herein individually as a “**Party**” and collectively as the “**Parties**”.

A. Pursuant to a certain asset purchase agreement, dated as of the date hereof, by and between Seller, Northern Mosaic Limited Partnership (a Manitoba limited partnership) and Assignee (as such agreement may be amended, restated or otherwise modified from time to time) (the “**Purchase Agreement**”), the Seller has agreed to effect, and to cause its applicable Affiliates to effect, the sale, assignment, transfer, conveyance and delivery of certain assets to Assignee, upon the terms and subject to the conditions set forth in the Purchase Agreement; and

B. Seller is willing to sell, assign, transfer, convey and deliver all of its rights in and to the Assigned Intellectual Property on the terms and subject to the conditions set forth in this Assignment.

For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by the Parties, Seller and Assignee agree as follows:

1. Definitions. Capitalized terms not otherwise defined herein shall have the meaning set forth in the Purchase Agreement.

2. Assignment. Effective as of the Effective Date, Seller hereby irrevocably sells, assigns, transfers, conveys and delivers to Assignee, in accordance with and subject to the terms of the Purchase Agreement:

(a) all of Seller’s and all of its other Affiliates’ right, title and interest in and to the Assigned Intellectual Property, including without limitation all rights of Seller under the patents and patent applications identified on Exhibit A (the “**Contributed Patents**”); and

(b) all of Seller’s rights of registration, maintenance, protection and defense in respect of the Assigned Intellectual Property (including, without limitation, those in respect of any interference proceedings and reexaminations involving the Assigned Intellectual Property), all of Seller’s rights to income, royalties, licence fees and other payments now due or hereafter due or payable in respect of the Assigned Intellectual Property, and all of Seller’s rights to sue and to claim, collect and retain damages and/or seek other remedies for past, present and future infringement or misappropriation of the Assigned Intellectual Property.

3. Authorization. Seller authorizes and requests the applicable Governmental Entities in any applicable jurisdictions, whose duty is to issue patents, trademarks or copyrights applications as aforesaid, to issue the same to Assignee and to record Assignee as owner of the Assigned Intellectual Property, as assignee of the entire right, title and interest in, to and under the

same, for the sole use and enjoyment of Assignee, its successors, assigns or other legal representatives.

4. Further Assurances. Seller shall provide (and Seller shall cause its Affiliates to provide) Assignee, its successors, assigns and legal representatives with all such assistance as it or they may reasonably request for the full utilization of the rights to the Assigned Intellectual Property granted in Section 2 above, including the execution and delivery of any affidavits, declarations, oaths, exhibits, assignments, powers of attorney or other documents, as may be necessary to effect, evidence or perfect the assignment of the Assigned Intellectual Property to the Assignee, or any assignee or successor thereto. Without limiting the foregoing, Seller shall promptly execute a confirmatory assignment in the form attached hereto as Exhibit B for each of the Contributed Patents.

5. Miscellaneous.

(a) Controlling Agreement. This Assignment is executed and delivered pursuant to, is in accordance with, and is subject to, all of the representations, warranties, covenants and miscellaneous provisions set forth in the Purchase Agreement, all of which shall survive the consummation of the transactions contemplated hereby on the basis and to the extent set forth in the Purchase Agreement. In the event that any provision of this Assignment shall be construed to conflict with a provision in the Purchase Agreement, the provision in the Purchase Agreement shall control.

(b) Governing Law. This Assignment shall be governed by and construed in accordance with the internal laws of the State of New York applicable to agreements made and to be performed entirely within such State, without regard to any conflict of law principles.

(c) Severability. If any provision of this Assignment (or any portion thereof) or the application of any such provision (or any portion thereof) to any Person or circumstance shall be held invalid, illegal or unenforceable in any respect by a court of competent jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision hereof (or the remaining portion thereof) or the application of such provision to any other Persons or circumstances.

(d) Waiver. No Person shall be deemed to have waived any claim arising out of this Assignment, or any power, right, privilege or remedy under this Assignment, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of such Person; and any such waiver shall not be applicable or have any effect except in the specific instance in which it is given. Furthermore, no failure on the part of any Person to exercise any power, right, privilege or remedy under this Assignment, and no delay on the part of any Person in exercising any power, right, privilege or remedy under this Assignment, shall operate as a waiver of such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy.

(e) Amendments. This Assignment may not be amended, modified, altered or supplemented other than by means of a written instrument duly executed and delivered on behalf of each Party.

(f) Counterparts. This Assignment may be executed by facsimile or electronic (.pdf) delivery of original signatures, and in counterparts, each of which shall be considered one and the same agreement, and shall become effective when such counterparts have been signed by each Party and delivered, including by facsimile or other electronic means, to the other Parties. No Party may raise (a) the use of a facsimile or email transmission to deliver a signature or (b) the fact that any signature, agreement or instrument was signed and subsequently transmitted or communicated through the use of a facsimile or email transmission as a defense to the formation or enforceability of a contract, and each Party forever waives any such defense.

(g) Binding Agreement. This Assignment shall be binding on and inure to the benefit of Seller and Assignee and their respective successors and assigns.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, the undersigned have executed this **INTELLECTUAL
PROPERTY ASSIGNMENT** on and as of the date first indicated above.

ASSIGNOR:

MOSAIC BIOMEDICALS, S.L.U.

ANIDO FOLGUEIRA
By: JUDIT - 40996668L Digitally signed by ANIDO
FOLGUEIRA JUDIT - 40996668L
Date: 2020.08.21 09:37:14 +02'00'
Name: Judit Anido
Title: General Manager

IN WITNESS WHEREOF, the undersigned has executed this **INTELLECTUAL
PROPERTY ASSIGNMENT** on and as of the date first indicated above.

ASSIGNEE:

MEDIMMUNE LIMITED


DocuSigned by:
By: 
Name: Greg Mueller
Title: Authorized Signatory

Exhibit A

Contributed Patents

| WSGR Docket No. (48885) | Country | Application No. (Patent No.) | Filing Date |
|--------------------------------------|----------------|---|--------------------|
| HUMANIZED ANTI-LIF ANTIBODIES | | | |
| 48885-704.611 | EP | 16382617.5 | 19-Dec-2016 |
| 48885-704.612 | EP | 17382683.5 | 13-Oct-2017 |
| 48885-704.101 | US | 62/467,017 | 3-Mar-2017 |
| 48885-704.601 | PCT | PCT/IB2017/001677 | 18-Dec-2017 |
| 48885-704.201 | US | 15/845,614 (10,583,191) | 18-Dec-2017 |
| 48885-704.401 | US | 15/880,906 (10,206,999) | 26-Jan-2018 |
| 48885-704.831 | US | 16/470,896 | 18-Dec-2017 |
| 48885-704.681 | AU | 2017381585 | 18-Dec-2017 |
| 48885-704.691 | BR | 1120190126910 | 18-Dec-2017 |
| 48885-704.701 | CA | 3,047,528 | 18-Dec-2017 |
| 48885-704.881 | CL | 201901717 | 18-Dec-2017 |
| 48885-704.711 | CN | 201780086859 | 18-Dec-2017 |
| 48885-704.591 | EA | 201991492 | 18-Dec-2017 |
| 48885-704.613 | EP | 17840489.3 | 18-Dec-2017 |
| 48885-704.741 | IN | 201917028822 | 18-Dec-2017 |
| 48885-704.731 | IL | 267450 | 18-Dec-2017 |

| WSGR Docket No. (48885) | Country | Application No. (Patent No.) | Filing Date |
|---|---------|---------------------------------|-------------|
| 48885-704.761 | JP | 2019-554037 | 18-Dec-2017 |
| 48885-704.781 | MX | MX/a/2019/007376 | 18-Dec-2017 |
| 48885-704.791 | NZ | 755004 | 18-Dec-2017 |
| 48885-704.821 | SG | 11201905574P | 18-Dec-2017 |
| 48885-704.9731 | SA | 519402119 | 18-Dec-2017 |
| 48885-704.841 | ZA | 2019/04533 | 18-Dec-2017 |
| 48885-704.771 | KR | 10-2019-7021098 | 18-Dec-2017 |
| 48885-704.861 | TH | 1901003761 | 18-Dec-2017 |
| 48885-704.9751 | AE | P6000892/2019 | 18-Dec-2017 |
| MSC1 DOSAGE FORMS | | | |
| 48885-714.611 | EP | 18382327.7 | 14-May-2018 |
| 48885-714.612 | EP | 18382359.0 | 25-May-2018 |
| 48885-714.613 | EP | 19382208.7 | 26-Mar-2019 |
| 48885-714.614 | EP | 19382331.7 | 3-May-2019 |
| 48885-714.601 | PCT | PCT/IB2019/000541 | 13-May-2019 |
| COMBINATIONS OF LIF ANTIBODIES AND PD-1 INHIBITORS | | | |
| 48885-715.611 | EP | 18382248.5 | 12-Apr-2018 |
| 48885-715.612 | EP | 18382326.9 | 14-May-2018 |
| 48885-715.613 | EP | 18382360.8 | 25-May-2018 |
| 48885-715.614 | EP | 19382132.9 | 22-Feb-2019 |

| WSGR Docket No. (48885) | Country | Application No. (Patent No.) | Filing Date |
|--|---------|---------------------------------|-------------|
| 48885-715.601 | PCT | PCT/IB2019/000423 | 11-Apr-2019 |
| LIF BIOMARKERS FOR USE WITH MSC-1 | | | |
| 48885-717.611 | EP | 18382433.3 | 18-Jun-2018 |
| 48885-717.601 | PCT | PCT/IB2019/000756 | 17-Jun-2019 |
| CISPLATIN/ANTI-LIF COMBO TREATMENTS | | | |
| 48885-718.611 | EP | 18382432.5 | 18-Jun-2018 |
| 48885-718.601 | PCT | PCT/IB2019/000812 | 17-Jun-2019 |
| PATIENT STRATIFICATION FOR LIF EXPRESSION | | | |
| 48885-719.611 | EP | 18382431.7 | 18-Jun-2018 |
| 48885-719.612 | EP | 19382131.1 | 22-Feb-2019 |
| 48885-719.601 | PCT | PCT/IB2019/000806 | 17-Jun-2019 |
| ANTIBODIES AGAINST LIF AND USES THEREOF | | | |
| 48885-723.101 | US | 62/774,460 | 03-Dec-2018 |
| 48885-723.102 | US | 62/943,479 | 04-Dec-2019 |